Details of the Drug

General Information of Drug (ID: DMCP3YO)

Drug Name

Blautix

Indication

Disease Entry	ICD 11	Status	REF
Irritable bowel syndrome	DD91.0	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Live biotherapeutic

Cross-matching ID

References

1	ClinicalTrials.gov (NCT03721107) A Phase II Randomized, Double Blind, Placebo-controlled, Parallel Group, Multicenter Study to Evaluate the Safety and Efficacy of Repeated Oral Doses of Blautix in Adult Subjects With Irritable Bowel Syndrome (IBS) Subtypes IBS-C and IBS-D. U.S.National Institutes of Health.